

MINDACT

Trial Highlights

The **M**icroarray **I**n **N**ode-negative (or 1-3 positive lymph node) **D**isease may **A**void **C**hemo**T**herapy (MINDACT) clinical trial is a study to help breast cancer patients and their physicians **optimize** chemotherapy treatment decisions using **MammaPrint®**

Here is a look at some of the impressive data from this **POSITIVE** trial:

112
Institutions



6,693



Early-stage breast cancer patients



FDA cleared



Covered by insurance

46%

of patients spared from unnecessary chemotherapy



Low Risk / High Risk results

HIGHEST



level of medical evidence

MammaPrint is a 70-gene test that will assess your cancer's risk of recurrence within 5-years. Patients diagnosed with stage I or II invasive breast cancer that is lymph node negative or lymph node positive (up to 3 nodes) and ≤ 5cm, are eligible for Agendia Breast Cancer testing.

Breast Cancer recurrence assay comparison:

	MammaPrint®	Oncotype DX®
Number of genes evaluated	70	16
Number of reference (or control) genes	465	5
FDA 510(k) cleared	✓	✗
Definitive Low Risk or High Risk Results? (No intermediate / indeterminate results)	✓	✗
Results don't reassess traditional breast cancer markers ER, PR, HER2 or Ki-67?	✓	✗
Results independent of 5 years of hormonal therapy or therapy compliance? (tamoxifen or AI)	✓	✗

MammaPrint data is based off of MINDACT publication results and information from www.agendia.com
 Oncotype DX data is based off of TAILORx study results and information from www.oncotypedx.com

Consult your physician to see if MammaPrint is right for you.



mammaprint®
70-Gene Breast Cancer Recurrence Assay